Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.690
+0.160 (10.46%)
At close: Jan 9, 2026, 4:00 PM EST
1.700
+0.010 (0.61%)
After-hours: Jan 9, 2026, 7:59 PM EST
Coherus Oncology Employees
Coherus Oncology had 228 employees as of December 31, 2024. The number of employees decreased by 78 or -25.49% compared to the previous year.
Employees
228
Change (1Y)
-78
Growth (1Y)
-25.49%
Revenue / Employee
$1,218,105
Profits / Employee
$679,697
Market Cap
204.27M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 228 | -78 | -25.49% |
| Dec 31, 2023 | 306 | -53 | -14.76% |
| Dec 31, 2022 | 359 | 27 | 8.13% |
| Dec 31, 2021 | 332 | 15 | 4.73% |
| Dec 31, 2020 | 317 | 26 | 8.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CHRS News
- 4 days ago - Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 days ago - Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114) - GlobeNewsWire
- 18 days ago - Coherus Oncology: A Two-Pronged March With Mid-2026 Implications - Seeking Alpha
- 4 weeks ago - Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma - GlobeNewsWire
- 2 months ago - Coherus Oncology, Inc. (CHRS) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 2 months ago - Coherus Oncology, Inc. (CHRS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody - GlobeNewsWire
- 2 months ago - Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire